Talquetamab improves patient reported symptoms and health related quality of life in relapsed or refractory multiple myeloma Results from the phase 12 MonumenTAL1 study Quiz

A 68-year-old male patient with relapsed/refractory multiple myeloma (RRMM) has undergone three prior lines of therapy including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. He is initiating treatment with talquetamab 0.8 mg/kg every other week. He reports significant baseline fatigue and pain impacting his quality of life. The patient is insured and motivated but concerned about potential side effects and symptom management.

Question: Based on the MonumenTAL-1 study findings, what should the pharmacist counsel the patient regarding expected changes in symptoms and quality of life during the initial treatment cycles with talquetamab?

A 72-year-old female with triple-class exposed RRMM is receiving talquetamab 0.8 mg/kg every other week. She reports mild oral discomfort and skin rash during the first two treatment cycles. She is concerned about these side effects and their impact on her treatment continuation and quality of life. She has a history of hypertension and is on lisinopril 10 mg daily.

Question: What is the most appropriate pharmacist intervention to optimize this patient’s treatment experience based on the MonumenTAL-1 study and related nursing considerations?

A 65-year-old male with heavily pretreated RRMM is undergoing treatment with talquetamab 0.8 mg/kg every other week. During a follow-up visit at cycle 21, his EORTC QLQ-C30 scores show a 5-point increase in global health status and a 12-point improvement in emotional functioning. He also reports decreased pain and fatigue. The patient asks what these changes mean for his overall health and treatment benefit.

Question: How should the pharmacist interpret and explain these patient-reported outcome changes based on the MonumenTAL-1 study results?